Herbal Marijuana Alternatives and Bath Salts-"Barely Legal" Toxic Highs

Clinical Pediatric Emergency Medicine

Volumn 13, Issue 4, 2012, Pages 283-291

  Lindsay, Laura ^a   White, Marjorie Lee ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Bath salts; Cannabinoids; Cathinones; Designer drugs; Drugs of abuse; Herbal marijuana; Spice; Sympathomimetic

Indexed keywords

3 (1 NAPHTHOYL) 1 PENTYLINDOLE; 3,4 METHYLENEDIOXYPYROVALERONE; 4' METHYLMETHCATHINONE; ALCOHOL; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BUTYLONE; CANNABINOID; CANNABINOID RECEPTOR; CATHINONE; CREATININE; DESIGNER DRUG; DEXANABINOL; DIAZEPAM; ETHACATHINONE; GLUTAMIC ACID; GLYCERYL TRINITRATE; HERBACEOUS AGENT; LORAZEPAM; METHYLENEDIOXYPYROVALERONE; METHYLONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITROPRUSSIDE SODIUM; PARACETAMOL; PROPOFOL; SALICYLIC ACID; SYNTHETIC CANNABINOID; SYNTHETIC CATHINONE; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENAL CORTEX DISEASE; AGGRESSION; AGITATION; ALCOHOL BLOOD LEVEL; ALERTNESS; ANXIETY DISORDER; ARTICLE; AUTOMUTILATION; BLOOD CLOTTING DISORDER; CLONUS; COMA; CONGESTIVE CARDIOMYOPATHY; CONJUNCTIVAL HYPEREMIA; CONVULSION; CREATININE BLOOD LEVEL; DELIRIUM; DELUSION; DIAPHORESIS; DISEASE SEVERITY; DIZZINESS; DOPAMINERGIC NERVE CELL; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EXPOSURE; DRUG FATALITY; DRUG INTOXICATION; DRUG LEGISLATION; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERANCE; DRUG TOXICITY; DUODENUM ULCER; ELECTROLYTE BLOOD LEVEL; EMPATHY; EUPHORIA; HEADACHE; HEART ARREST; HEART INFARCTION; HEART PALPITATION; HOPELESSNESS; HUMAN; HYPERREFLEXIA; HYPERTENSION; HYPERTHERMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTHERMIA; INTUBATION; IRRITABILITY; KIDNEY FAILURE; KIDNEY FUNCTION TEST; LIBIDO; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; MEMORY DISORDER; MENTAL DISEASE; MULTIPLE ORGAN FAILURE; MUSCLE TWITCH; MYDRIASIS; NAUSEA; NEUROMUSCULAR BLOCKING; NEUROTOXICITY; PALLIATIVE THERAPY; PARANOIA; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; RESTLESSNESS; SEDATION; SEIZURE; SEROTONIN SYNDROME; SEROTONINERGIC NERVE CELL; SIDE EFFECT; SPICE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SWEATING; TACHYCARDIA; TACHYPNEA; TANDEM MASS SPECTROMETRY; THORAX PAIN; TOXICOLOGY; TREATMENT FAILURE; TREATMENT INDICATION; UREA NITROGEN BLOOD LEVEL; VERTIGO; VOMITING; XEROSTOMIA;

EID: 84874480616     PISSN: 15228401     EISSN: 15582310     Source Type: Journal    
DOI: 10.1016/j.cpem.2012.09.001     Document Type: Article

References (45)

1. Sullivan L. Designer drug ODs call for supportive care and education. Available at: www.acepnews.com, January 2012. Accessed January 1, 2012. Supplemented by personal communication with Mark B. Mycyk, MD.
2. Mycyk M.B. Emerging drugs of abuse: what was new yesterday is new today. J Med Toxicol 2012, 8:1-2.
3. Bronstein A.C., Spyker D.A., Cantilena L.R., et al. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol 2011, 49:933-940.
4. Rosenbaum C.D., Carreiro S.P., Babu K.M. Here today, gone tomorrow. .and back again? A review of herbal marijuana alternatives [K2, spice], synthetic cathinones [bath salts], kratom, Salvia divinorum, methoxetamine, and piperazine. J Med Toxicol 2012, 8:15-32.
5. Pertwee R.G., Howlett A.C., Abood M.E., et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol Rev 2010, 62:588-631.
6. Mir A., Obafemi A., Young A., et al. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011, 128:e1-e6.
7. Schneir A.B., Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol 2012, 8:62-64.
8. Zuba D., Byrska B., Maciow M. Comparison of "herbal highs" composition. Anal Bioanal Chem 2011, 400:119-126.
9. Advisory Council on the Misuse of Drugs. Consideration of the cathinones. Available at: Accessed May 29, 2012. http://www.homeoffice.gov.uk/acmd1/acmd-cathinodes-report-2010?view=Binary.
10. Di Marzo V., Bifulco M., De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004, 3:771-784.
11. Cohen J., Morrison S., Greenberg J., et al. Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics 2012, 129:e1064-e1067.
12. Filbert M., Levine E., Ballough G. Neuroprotection for nerve agent-induced brain damage by blocking delayed calcium overload: a review. J Med CBR Def 2005, 3:1-10.
13. Every-Palmer S. Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction 2010, 105:1859-1860.
14. Vearrier D., Osterhoudt K.C. A teenager with agitation: higher than she should have climbed. Pediatr Emerg Care 2010, 26:462-465.
15. Nicholson P.J., Quinn M.J., Dodd J.D. Headshop heartache: acute mephedrone 'meow' myocarditis. Heart 2010, 96:2051-2052.
16. Today Health. 'Spice' drug tied to kidney failure cases in Wyoming, March 4, 2012. Available at: Accessed July 1, 2012. http://today.msnbc.msn.com/id/46619223/ns/today-today_health/t/spice-drug-tied-kidney-failure-cases-wyoming/.
17. NMS labs. K2, Spice and other synthetic cannabinoids testing. Available at: Accessed July 1, 2012. http://www.nmslab.com/services-forensic-K2-testing.
18. Gibbons S. 'Legal highs'-novel and emerging psychoactive drugs: a chemical overview for the toxicologist. Clin Toxicol 2012, 50:15-24.
19. Prosser J.M., Nelson L.S. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012, 8:33-42.
20. Centers for Disease Control and Prevention Emergency department visits after use of a drug sold as "bath salts": Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep 2011, 60:624-627.
21. American Association of Poison Control Centers. US poison centers raise alarm about toxic substances marketed as bath salts. Available at: Accessed May 29, 2012. http://www.aapcc.org/dnn/Portals/0/prrel/bathsalts-final.pdf.
22. Krikku P., Wilhelm L., Schwarz O., et al. New designer drug of abuse: 3,4-methylenedioxypyrovalerone [MDPV]. Findings from apprehended drivers in Finland. Forensic Sci Int 2011, 210:195-200.
23. Winstock A.R., Mitcheson L.R., Deluca P., et al. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
24. Dargan P.I., Albert S., Wood D.M. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 2010, 103:875-879.
25. Al-Motarreb A., Al-Habori M., Broadley K.J. Khat chewing, cardiovascular disease and other internal medical problems; the current situation and directions for future research. J Ethnopharmacol 2010, 132:540-548.
26. Breneisen R., Fisch H.U., Koelving U., et al. Amphetamine-like effects in humans of the khat alkaloid cathinone. Br J Clin Pharmacol 1990, 30:825-828.
27. Hill S.L., Thomas S.H.L. Clinical toxicology of newer recreational drugs. Clin Toxicol 2011, 49:705-719.
28. James D., Adams R.D., Spears R., et al. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J 2010, 28:686-689.
29. Davies S., Wood D.M., Smith G., et al. Purchasing 'legal highs' on the Internet-is there consistency in what you get?. QJM 2010, 103:489-493.
30. Meyer M.R., Wilhelm J., Peters F.T., et al. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 2010, 397:1225-1233.
31. Winstock A., Mitcheson L., Ramsey J., et al. Mephedrone: use, subjective effects and health risks. Addiction 2011, 106:1991-1996.
32. Schifano F., Albanese A., Fergus S., et al. Mephedrone[4-methylmethcathinone; 'meow meow']: chemical pharmacological and clinical issues. Psychopharmacology 2011, 214:593-602.
33. McCann U.D., Wong D.F., Yokoi F., et al. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11c]WIN-35,428. J Neurosci 1998, 18:8417-8422.
34. Archer R.P. Fluromethcathinone, a new substance of abuse. Forensic Sci Int 2009, 185:10-20.
35. Sammler E.M., Foley P.L., Lauder G.D., et al. A harmless high?. Lancet 2010, 376:742.
36. Boulanger-Gobeil C., St.-Onge M., Laliberte M., Auger P.L. Seizures and hyponatremia related to ethacathinone and methylone poisoning. J Med Toxicol 2012, 8:59-61.
37. Warrick B.J., Wilson J., Hedge M., et al. Lethal serotonin syndrome after methylone and butylone ingestion. J Med Toxicol 2012, 8:65-68.
38. Murray B.L., Murphy C.M., Beuhler M.C. Death following recreational use of designer drug "Bath Salts" containing 3,4-methylenedioxypyrovalerone (MDPV). J Med Toxicol 2012, 8:69-75.
39. Borek H.A., Holstege C.P. Hyperthermia and multiorgan failure after abuse of "Bath Salts" containing 3.4-methylenedioxypyrovalerone. Ann Emerg Med 2012, 60:103-105.
40. Mugele J., Nanagas K.A., Tormoehlen L.M. Serotonin syndrome associated with MDPV use: a case report. Ann Emerg Med 2012, 60:100-102.
41. Frison G., Gregio M., Zamengo L., et al. Gas chromatography/mass spectrometry determination of mephedrone in drug seizures after derivatization with 2,2,2-trichloroethyl chloroformate. Rapid Commun Mass Spectrom 2011, 25:387-390.
42. Wissenbach D.K., Meyer M.R., Remane D., et al. Drugs of abuse screening in urine as part of a metabolite-base LC-MS[n] screening concept. Anal Bioanal Chem 2011, 400:3481-3489.
43. Torrance H., Cooper G. The detection of mephedrone [4-methylmethcathinone] in 4 fatalities in Scotland. Forensic Sci Int 2010, 202:e62-e63.
44. National Conference of State Legislatures. Synthetic drug threats. Available at: Accessed July 1, -2012. http://www.ncsl.org/issues-research/justice/synthetic-drug-threats.aspx.
45. Govtrack.us. S.605: dangerous synthetic drug control act of 2011. Available at: Accessed July 2, 2012. http://www.govtrack.us/congress/bills/112/s605/text.